Siirry sisältöön

In vitro -diagnostiikka (IVD)

Labmaster LUCIA™ SARS-CoV-2 IgG NP -testipakkaus kokoverinäytteille

Labmaster LUCIA™ SARS-CoV-2 IgG NP testi on in vitro diagnostinen vieritesti kvalitatiiviseen SARS-CoV-2 nukleiiniproteiinin (NP:n) IgG-vasta-aineiden tunnistamiseen kokoverestä (litiumhepariini).  

NP-testi on tarkoitettu tukemaan SARS-CoV-2 adaptiivisen immuunivasteen tunnistamista henkilöiltä, joilla epäillään COVID‑19 -tartuntaa tai altistumista SARS‑CoV‑2-virukselle. NP-testi on tarkoitettu tarkoitettu  terveydenhuollon  ammattilaisten  käytettäväksi puoliautomaattisen Labmaster LUCIA™ -analysaattorin kanssa.




7 µL


6 minuuttia


77 %


100 %


+2 – +8 °C

  • Vieritesti voidaan suorittaa sormenpääverinäytteestä
  • Tulos valmistuu 6 minuutissa
  • Yksinkertainen testimenetelmä
  • Testipakkaus sisältää testin suorittamiseen tarvittavat reagenssit ja laimennuspuskurin
LM176 Labmaster LUCIA™ SARS-CoV-2 IgG NP Kit for Whole Blood Samples CE-marked IVD Each kit contains 40 ready-to-use tests

Contents of the kit:

SARS-CoV-2 IgG NP Cassette 40 pcs
SARS-CoV-2 IgG NP Dilution Tube for Whole Blood sample 0.84 mL x 40 pcs
Li-Heparin coated capillaries (7 µL) 2 x 50 pcs
Plungers for capillaries 2 x 50 pcs
SARS-CoV-2 IgG NP NFC Card 1 pc
NP Instructions for Use and Quick Guide 1 pc

The following components are required but not included in the kit: 

Labmaster LUCIA™ Analyzer LM26
Labmaster LUCIA™ Analyzer Instructions for Use LM28
Lancets for fingertip blood sample N/A

The SARS-CoV-2 Nucleocapsid Protein (NP) is a multifunctional RNA-binding protein, which is not only responsible for packaging viral genomes but also regulates the innate immune response caused by viral infection. Compared with other potential SARS-CoV-2 antigens, the NP antigen has some distinct advantages, including the conservation of the NP sequence, the expanding knowledge of its genetics and biochemistry, and its strong immunogenicity (i).
The presence of antibodies against SARS-CoV-2 NP pathogen in blood indicates adaptive immune response to recent or prior infection. Antibody responses to SARS-CoV-2 can be detected in most individuals 10–15 days after the onset of COVID-19 symptoms (ii).

(i) Bai Z. et al. 2021. The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation. Viruses 13.
(ii) Seow J. et al. 2020. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology 5; 1598–1607.


Puh. +358 22 760 555
Rauhalinnantie 31, 20780 KAARINA, Finland

Legal disclaimer
Products designed, developed and manufactured by Labmaster Ltd. meet their specifications when stored, used and transported according to the instructions for use and product inserts. Labmaster LUCIA™ is a trademark designed and owned by Labmaster Ltd.

Not all products are available in all regions. Check with your local representative for availability in specific markets.

Vieritä ylös